An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients-Reference-Cited by-同舟云学术

An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients

Published:2018-10-22 Issue: Volume:9 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Bassolas-Molina Helena,Raymond Ernest,Labadia Mark,Wahle Joseph,Ferrer-Picón Elena,Panzenbeck Mark,Zheng Jie,Harcken Christian,Hughes Robert,Turner Michael,Smith Dustin,Calderón-Gómez Elisabeth,Esteller Míriam,Carrasco Anna,Esteve Maria,Dotti Isabella,Corraliza Ana Maria,Masamunt Maria Carme,Arajol Clàudia,Guardiola Jordi,Ricart Elena,Nabozny Gerald,Salas Azucena

Funder

Leona M. and Harry B. Helmsley Charitable Trust

Boehringer Ingelheim

European Regional Development Fund

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference42 articles.

1. Increased expression of interleukin 17 in inflammatory bowel disease;Fujino;Gut,2003

2. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease;Rovedatti;Gut,2009

3. Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients;Veny;AlimentPharmacolTher.,2010